

Coline H M Van Moorsel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3811582/publications.pdf>

Version: 2024-02-01

28
papers

1,089
citations

687363

13
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

1428
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2018, 379, 2209-2219.	27.0	326
2	Surfactant Protein C Mutations Are the Basis of a Significant Portion of Adult Familial Pulmonary Fibrosis in a Dutch Cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1419-1425.	5.6	252
3	Telomere Length in Interstitial Lung Diseases. <i>Chest</i> , 2015, 148, 1011-1018.	0.8	98
4	Short telomere length in IPF lung associates with fibrotic lesions and predicts survival. <i>PLoS ONE</i> , 2017, 12, e0189467.	2.5	87
5	Effect of <i>MUC5B</i> promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. <i>Respirology</i> , 2016, 21, 712-717.	2.3	50
6	SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility: A Joint Analysis in Four European Populations. <i>Frontiers in Immunology</i> , 2017, 8, 422.	4.8	31
7	<i>YKL40</i> , <i>CCL18</i> and <i>SPD</i> predict mortality in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2017, 22, 542-550.	2.3	27
8	Clinical epidemiology of familial sarcoidosis: A systematic literature review. <i>Respiratory Medicine</i> , 2019, 149, 36-41.	2.9	26
9	The <i>MUC5B</i> promoter risk allele for idiopathic pulmonary fibrosis predisposes to asbestosis. <i>European Respiratory Journal</i> , 2020, 55, 1902361.	6.7	23
10	From organ to cell: Multi-level telomere length assessment in patients with idiopathic pulmonary fibrosis. <i>PLoS ONE</i> , 2020, 15, e0226785.	2.5	19
11	The <i>MUC5B</i> Promoter Polymorphism Associates With Severe COVID-19 in the European Population. <i>Frontiers in Medicine</i> , 2021, 8, 668024.	2.6	18
12	Systematic review of drug effects in humans and models with surfactant-processing disease. <i>European Respiratory Review</i> , 2018, 27, 170135.	7.1	17
13	<i>MUC5B</i> promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 996-1004.	3.4	17
14	Telomere dysfunction implicates <i>POT1</i> in patients with idiopathic pulmonary fibrosis. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	17
15	Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	16
16	Pulmonary fibrosis linked to variants in the <i>ACD</i> gene, encoding the telomere protein TPP1. <i>European Respiratory Journal</i> , 2019, 54, 1900809.	6.7	14
17	Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis. <i>Respirology</i> , 2018, 23, 311-317.	2.3	13
18	Pulmonary fibrosis in non-mutation carriers of families with short telomere syndrome gene mutations. <i>Respirology</i> , 2021, 26, 1160-1170.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis. <i>Biomarkers in Medicine</i> , 2020, 14, 997-1007.	1.4	5
20	To progress understanding of disease triggers and modifiers in sarcoidosis, stratification is the key. <i>European Respiratory Journal</i> , 2017, 50, 1702002.	6.7	4
21	Clustering of lung diseases in the family of interstitial lung disease patients. <i>BMC Pulmonary Medicine</i> , 2022, 22, 134.	2.0	4
22	Non-specific and Usual Interstitial Pneumonia, Short-Term Survival After Surgical Biopsy. <i>Lung</i> , 2015, 193, 449-450.	3.3	3
23	Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease. <i>Lung</i> , 2021, 199, 659-666.	3.3	3
24	The importance of biobank and nationwide registry for lymphangiomyomatosis in a small sized country. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 393-401.	0.8	2
25	Is there evidence for anti-TNF drugs in joint involvement in sarcoidosis?. <i>Immunotherapy</i> , 2015, 7, 601-601.	2.0	2
26	Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy. <i>Case Reports in Pulmonology</i> , 2013, 2013, 1-3.	0.3	1
27	Correspondence for "Clinical epidemiology of familial sarcoidosis: A systematic literature review". <i>Respiratory Medicine</i> , 2019, 160, 105753.	2.9	1
28	Putting Genetics Into Practice. <i>Chest</i> , 2020, 158, 2249-2250.	0.8	0